Pan
Li‡
*ab,
Zihe
Zhai‡
c,
Jiawen
Fang‡
a,
Ruo
Wang
b,
Weiqi
Li
a,
Beiduo
Wang
c,
Jinglei
Wang
a,
Jiaqi
Zhu
b,
Feng
Bing
b,
Qiaoling
Pan
b,
ChangYou
Gao
*c and
ShaoHong
Lu
*a
aEngineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, 310051, China. E-mail: llsshh2003@163.com; panli0706@zju.edu.cn; 881012022054@hmc.edu.cn; 17662433651@163.com; 21818015@zju.edu.cn; 13305470636@163.com
bState Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City, 310003, China. E-mail: wangruo1998@zju.edu.cn; 11818073@zju.edu.cn; qiaolingpan@zju.edu.cn
cMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, China. E-mail: cygao@zju.edu.cn; zhaizh@zju.edu.cn; bdwang10@zju.edu.cn
First published on 4th June 2024
Together, tumor and virus-specific tissue-resident CD8+ memory T cells (TRMs) of hepatocellular carcinoma (HCC) patients with Hepatitis B virus (HBV) infection can provide rapid frontline immune surveillance. The quantity and activity of CD8+ TRMs were correlated with the relapse-free survival of patients with improved health. However, HBV-specific CD8+ TRMs have a more exhausted phenotype and respond more actively under anti-PDL1 or PD1 treatment of HBV+HCC patients. Vaccination strategies that induce a strong and sustained CD8+ TRMs response are quite promising. Herein, a biodegradable poly(D,L-lactide-co-glycolide) microsphere and nanosphere particle (PLGA N.M.P) delivery system co-assembled by anti-PD1 antibodies (aPD1) and loaded with ovalbumin (OVA-aPD1 N.M.P) was fabricated and characterized for size (200 nm and 1 μm diameter), charge (−15 mV), and loading efficiencies of OVA (238 μg mg−1 particles) and aPD1 (40 μg mg−1 particles). OVA-aPD1 N.M.P could stimulate the maturation of BMDCs and enhance the antigen uptake and presentation by 2-fold compared to free OVA. The nanoparticles also induced the activation of macrophages (RAW 264.7) to produce a high level of cytokines, including TNF-α, IL-6 and IL-10. In vivo stimulation of mice using OVA-aPD1 N.M.P robustly enhanced IFN-γ-producing-CD8+ T cell infiltration in tumor tissues and the secretion of IgG and IgG2a/IgG1 antibodies. OVA-aPD1 N.M.P delivered OVA to increase the activation and proliferation of OVA-specific CD8+ TRMs, and its combination with anti-PD1 antibodies promoted complete tumor rejection by the reversal of tumor-infiltrating CD8+ T cell exhaustion. Thus, PLGA N.M.P could induce a strong CD8+ TRMs response, further highlighting its therapeutic potential in enhancing an antitumor immune response.
Liver CD8+TRMs are unique T cells residing in the liver that exert local immune surveillance including cytolytic activity and secretion of proinflammatory cytokines such as IFN-γ and TNF-α.10,11 They act as the first line of defense by directly lysing target cells and also confer protective functions through the recruitment of circulating T cells or other immune cells via chemokine production. CD8+TRMs generally express adhesion and retention molecules including CD103, CD69, CD49a, CD44, and chemokine receptors CXCR3 and CXCR6, but not all of these markers are expressed in all populations of TRMs, indicating the nuance among different TRMs subsets.12,13 CD8+TRMs were highly enriched in the setting of HBV infection compared with healthy livers, with a mean 3-fold increase in frequency, accounting for up to 68.5% of all intrahepatic memory CD8+ T cells.14
Increasing studies find the intra-tumoral HBV-specific CD103+CD69+CD8+ TRMs correlated with the improved prognosis of HBV+HCC patients. Furthermore, the degree of infiltration of CD8+ TRMs is associated with good prognosis of malignant tumors such as lung cancer15 and melanoma.16 Thus, a feasible immune intervention therapy approach is to reverse the immune microenvironment by targeting the activation of the non-tumor specific CD8+ TRMs, and then further improving the tumor-specific T cells to activate and proliferate through the crosstalk between cytokines or chemical factors among immune cells.
Poly(lactic-co-glycolic acid) (PLGA) is a widely used material with good biodegradable and biocompatibility.17 Particles in the nano (NP) and micron (MP) range are the most commonly used and extensively studied vaccine carrier polymers. Antigens can be adsorbed and encapsulated into the particle core or the polymer matrix, as well as conjugated to the building blocks or the particle surface.18,19 This biomaterial-based delivery system can enhance the uptake of either antigens or adjuvants by antigen-presenting cells (APCs), and is associated with better immune responses than those obtained with the soluble counterparts. Meanwhile, the prolonged release of antigens can provide more effective immune responses, and also avoid the risk of tolerance and substitute the need of several boosting administrations typically required to induce protective immunity.20,21
HBV is a strict hepatotropic virus, and mice are not permissive to HBV infection. Thus, the lack of an appropriate mouse model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection-related HCC. Here, we assumed OVA (257–264) specific CD8+ TRMs as non-tumor antigen specific CD8+ TRMs in a HCC mouse model, and then prepared OVA-aPD1 N.M.P as a vaccine delivery system that was constructed by PLGA nano and microparticles. The inside of the particles was encapsulated with anti-mouse PD1 antibody (aPD1) and the surface was loaded with OVA(257–264) peptides, providing the OVA-aPD1 N.M.P with the ability to activate hepatic OVA-specific (non-tumor antigen specific) CD8+ TRMs. The function of the exhausted HCC specific CD8+ TRMs is then restored and the PD1 immunotherapy response is improved by cross-talking with other immune cells, which can then be available as a potential immune-therapeutic target in future HBV-related HCC.
The obtained emulsions were magnetically stirred under room temperature for 2 h to completely evaporate the CH2Cl2. Finally, the particles were collected by centrifugation and washed with ddH2O for 3 times. The NPs and MPs were re-dispersed in PBS, mixed at a ratio of 1:
1 (w/w) to obtain the empty NPs and MPs (Emp. N.M.P), and antibody and antigen loaded NPs and MPs (OVA-aPD1 N.M.P), respectively. The particles were kept at −20 °C before use. To prepare the fluorescent-labelled particles, OVA-FITC (Beijing Solarbio Science & Technology Co., Ltd, China) was added to the PLGA solution, and the following procedure was the same as that for the empty PLGA particles.
The morphology of the particles was observed by scanning electron microscopy (SEM). The particle suspension (10 μL) was dripped onto a glass slide and dried at room temperature overnight, and then observed by SEM (S-4800, Hitachi, Japan) at an acceleration voltage of 3 kV. The size and zeta potential of the particles were measured by dynamic light scattering (DLS) (Nano-ZS, Malvern, UK).
The content of OVA coated on the particle surface was measured by the Bradford Assay Kit (Thermo Scientific, USA) according to the manufacturer's instructions. Briefly, the loaded particles (10 mg) were suspended in 1 ml 1 M sodium hydroxide (NaOH), and agitated at 250 rpm using an electronic shaker for 3 h at room temperature (RT) to hydrolyse the polymer. A 3 ml volume of PBS (pH 7.4) and 1 ml 1 M hydrochloride acid (HCl) were added to the PLGA–NaOH mixture. The resultant sample (0.1 ml) was mixed with 2 ml BCA reagents A and B (50:
1). The absorbance of the above solution was measured using UV-vis spectroscopy at 557 nm. Each measurement was repeated in triplicate. A calibration curve was prepared at BSA concentrations of 20, 40, 80, 120, 160 and 200 mg ml−1.
The aPD1 loading contents were calculated according to the unloaded antibody in the centrifugal supernatant measured by ELISA. The loading capacity (L.C.) and encapsulation efficiency (E.E.) of the aPD1-encapsulated nanoparticles were determined by measuring the amount of nonencapsulated IgG through a mouse monoclonal antibody ELISA. The IgG Rat ELISA Kit was purchased from Thermo Fisher Scientific Inc. LC and EE were calculated as LC = (A − B)/C, EE = (A − B)/A, where A was the expected encapsulated amount of antibody, B was the free amount of antibody in the collection solution, and C was the total weight of the particles.
Mouse BMDCs were prepared according to the previous method.22 Briefly, bone marrow cells were isolated from the femur and tibia of female C57BL/6 mice (6–8 weeks), and then cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (Hyclone) supplemented with GM-CSF (20 ng mL−1) and IL-4 (10 ng mL−1). The culture media were replaced every 2 days. On day 6, non-adherent immature DCs (iDCs) were harvested for further evaluation.
To quantitatively determine the effect of PLGA N.M.P on the cellular uptake of the antigen, iDCs were cultured with free FITC-OVA, or that formulated in nano/micro-particles, and the OVA loading for the particle formulations was set at 238 μg OVA per 1 mg particles. The antigen endocytosis and presentation were analyzed by measuring OVA-FITC positive DCs (CD11c+CD11b+) using flow cytometry (BD LSRFortessa). For intracellular antigen localization, iDCs were cultured with free OVA-FITC or N.M.P-formulated OVA-FITC. After 24 h, cell membranes were labeled with Alexa FluorVR 594 phalloidin, and intracellular localization of OVA was examined by a confocal laser scanning microscope (CLSM, Leica TCS SP8).
To evaluate the iDCs activation and maturation, iDCs were stimulated with OVA-aPD1 N.M.P, medium, equal amounts of free OVA and aPD1 (OVA-aPD1), Emp. N.M.P, and PMA/Ionomycin for 24 h and 48 h, respectively. Then, the iDCs were collected and stained with fluorophore-labeled antibodies, including Brilliant Violet 510™ anti-mouse CD11b (Biolegend, cat. #101263), FITC anti-mouse CD80 (Biolegend, cat. #104706), APC anti-mouse CD86 (Biolegend, cat. #v105012), PE/Cyanine7 anti-mouse CD11c (Biolegend, cat. #117318), BD Horizon™ V500 Rat Anti-Mouse I-A/I-E (BD Bioscience, cat. #562366) and life/dead Zombie Aqua™ Fixable Viability Kit (Biolegend, cat. #423101). Finally, the redundant antibodies were removed through centrifugation, and the stained cells were analyzed using flow cytometry (CytoFlex LX).
For the inflammatory activation level of the vaccine towards DCs and RAW264.7 macrophages, the cytokine concentrations of IL-12p70, IL-10, TNF-α of DCs, and TNF-α, IL-6, IL-10 of RAW264.7 cells were determined by ELISA. Briefly, RAW264.7 cells and BMDCs were seeded into 96-well plates separately, and then incubated with naked or particles formulated OVA-aPD1, 24 h and 48 h later. The concentrations of different cytokines in the supernatant of each sample were determined according to the manufacturer's protocol.
For the establishment of the liver cancer mouse, mice were hydrodynamically injected with a 5:
1
:
1 molar ratio of transposon to transposase-encoding plasmid (26 μg total DNA) via the tail vein. Two weeks later, the high dose OVA antigen immunization was continued for 14 days. Both the activity and quantity of the tumor specific and non-tumor (OVA) specific CD8+ TRMs of these mice were confirmed by flow cytometry (CytoFlex LX). Then, these mice were randomly divided into four groups with 10 mice in each group, and immunized with various formulations, including PBS, Emp. N.M.P, OVA-aPD1, and OVA-aPD1 N.M.P by tail vein injection with a pre-determined immunization dose of 3 times at 1 week intervals. To test the effect of particles on the CD8+ TRMs, half of the mice in each group were administered i.v. with 50 μg FTY720 (SML0700, SIGMA), which dissolved in 0.9% NaCl, and at a time period starting 1 week before the fourth vaccine immunization.
Blood was collected before every injection. Whole blood was centrifuged at 1000g to isolate the serum, which was then collected and stored at −80 °C until use. Fourteen days after the last immunization, the mice were sacrificed. The liver lymphocytes were isolated, and then the liver was washed with PBS and minced after perfusion. This was followed by enzymatic digestion with collagenase IV (Sigma, V900893), deoxyribonuclease type I (Sigma, D5025), and hyaluronidase type V (Sigma, H3506) at 37 °C for 30 min. Finally, the sample was filtered through the 70-mesh filter screen. After being washed with cell staining buffer (CSB, PBS containing 0.5% OVA and 0.02% NaN3), the cell pellets were resuspended into ACK lysing buffer to remove the red blood cells. The rest of the single cells were processed using the Percoll density gradient media (GE Healthcare) to get rid of fats and debris, followed by washing twice with wash buffer.
Intracellular cytokine staining TILs were stimulated in vitro with Phorbol 12-Myristate 13-Acetate (PMA) (50 ng mL−1) and Ionomycin (1 mg mL−1; Sigma-Aldrich) or soluble OVA257–264-peptide (50 mg mL−1) separately in the presence of GolgiPlug (BD Biosciences; 1:
1000) and GolgiStop (BD Biosciences; 1
:
1500) for 3–4 hours. Cells were washed twice and resuspended in FACS wash buffer for staining with cell surface monoclonal antibodies (mAbs), and subsequently fixed, permeabilized and stained with anti-mouse IFN-γ and TNF-α monoclonal antibody (mAb) cocktail for flow cytometry analysis.
Particles | Particle size (nm, mean ± SD) | Polydispersive index (PDI, mean ± SD) | Loading content (μg mg−1 particles) | Zeta potential (mean ± SD) | |
---|---|---|---|---|---|
Peak 1 size (nm) & intensity (%) | Peak 2 size (nm) & intensity (%) | ||||
OVA + aPD1 N.M.P. | 203 ± 68 nm, 7.07 | 1.3 ± 0.6 μm, 10.1 | 0.194 ± 0.026 | OVA (238); aPD1 (40) | −8.92 ± 0.22 |
Emp. N.M.P. | 295 ± 25 nm, 8.23 | 1.3 ± 0.4 μm, 12.9 | 0.128 ± 0.115 | — | −14.93 ± 0.55 |
Another important signal is mediated by the engagement of co-stimulatory molecules, such as B7.1 (CD80) and B7.2 (CD86), on APC and CD28 on the T cells. These two signals start a cross-talk between the T cells and APCs, which both release cytokines that collectively will define the inflammatory milieu. DCs are the main type of phagocytic cells, and play an important role in initiating adaptive immune responses. On sensing dangerous signals through their pattern recognition receptors (PRRs), iDCs undergo maturation while migrating to the secondary lymphoid organs to prime T cells.25,26 So, the effect of PLGA N.M.P on the activation and maturation of BMDCs was also assessed. The activation of iDCs is commonly accompanied with the expression of several co-stimulatory factors. Upon stimulation with different antigen formulations and controls, the expression of surface markers of iDCs (including CD86, CD80 and MHCII) was examined by FACS. The loop gate rule of mature DCs is shown in Fig. 1G. The OVA-aPD1 N.M.P significantly enhanced the proportion of CD86+CD80+MHCII+ DCs (Fig. 1H). Persistent production of IL-12 by iDCs during active infection was indispensable for the polarization and maintenance of the Th1 response.27 Here, the concentration of IL-12p70 in the supernatant of DCs incubated with different stimulators was determined. Although free OVA-aPD1 significantly enhanced the secretion of IL-12p70, the OVA-aPD1 N.M.P-treated group even displayed a similar IL-12p70 level in comparison with the positive control of PMA/Ionomycin. Based on these results, we can conclude that the PLGA micro/nanoparticles facilitated the endocytosis of the antigen, and the production of inflammatory cytokines significantly promoted the activation and maturation of iDCs (Fig. 1I). Cytokine secretion of IL-10 (Fig. 1J) and TNF-α (Fig. 1K) in the culture supernatant are up-regulated compared to the control cells, indicating the activation and maturation of iDCs.
Apart from DCs, macrophages also play a pivotal role in the initiation of adaptive immune responses by recruiting and activating NK cells and T and B lymphocytes.28 The cytokine production by RAW 264.7 macrophages was determined in vitro after stimulation with different stimulators. The concentration of TNF-α (Fig. 1L), IL-10 (Fig. 1M) and IL-6 (Fig. 1N) was detected, and OVA-aPD1 N.M.P greatly increased the cytokine secretion. These results indicate that the nano and micro particles were able to assist the M1 polarization.
The mouse modeling and therapy scheme are shown in Fig. 2A. Mice were randomly divided into four groups with 10 mice in each group, and immunized with various formulations, including PBS, Emp. N.M.P, OVA-aPD1, and OVA-aPD1 N.M.P, by tail vein injection with a pre-determined immunization dose 3 times at 1 week interval. To test the effect of particles on CD8+ TRMs, half of the mice in each group was administered i.v. with 50 μg FTY720 (SML0700, SIGMA), which dissolved in 0.9% NaCl, and starting 1 week before the fourth vaccine immunization.
The level of cellular and humoral immune response was detected based on IgG titer and cytokine concentration by ELISA. OVA-aPD1 N.M.P induced a significantly higher IgG response at 7 days after the last immunization. Free OVA-aPD1 also elicited an IgG response, but it was much lower than that of the immunotherapy group (Fig. 2B). The OVA-specific IgG1 and IgG2a levels were also measured to determine the types of T helper (Th) cell immune responses. In comparison with IgG1, more IgG2a is produced from the OVA-aPD1 N.M.P and free OVA-aPD1 groups (Fig. 2C). Furthermore, the IgG2a/IgG1 ratio is statistically significantly higher in the OVA-PD1 N.M.P group, indicating a mixed Th1/Th2 response when the Th1 bias response was aroused (Fig. 2D).
The concentrations of the cytokines in serum, which was collected at 7, 14, and 21 days after the first immunization, were evaluated. IL-2 emerged to be a key cytokine in regulating the survival, proliferation, and differentiation of activated T cells. IFN-γ and TNF-α play key roles in cellular immune processes and could promote Th1 responses. The secretion of IL-2 (Fig. 2E), IFN-γ (Fig. 2F), and TNF-α (Fig. 2G) was enhanced with the boost and third immunization. The OVA-aPD1 N.M.P induced a significantly higher level of Th1-type cytokines (IL-2, IFN-γ and TNF-α) compared to the other groups (P < 0.05). IL-4 acted directly on tumor cells as a tumor promoting cytokine. Furthermore, IL-4 contributed to the establishment and maintenance of Th2-polarized immune responses, reduced the tumoricidal activity of CD8+ T cells, and indirectly impaired the antitumor immunity in tumor-bearing animals or cancer patients. The two formulations of OVA-aPD1 induced a lower production of IL-4 (Fig. 2H). These results suggest that OVA-aPD1 N.M.P robustly augmented both humoral and cellular immune responses, especially a potent Th1 immune response in vivo.
CD8+ TRMs acted as a facilitator that can secrete various cytokines, such as IFN-γ, TNF-α, and IL-2, with triggering adaptive and innate immune responses rapidly including DC maturation, NK cell activation, and B cell recruitment.10 Here, mice were treated with FTY720 to block the memory lymphocyte migration from the lymph nodes to the infected tissue. After the fourth immunization, we find that both OVA-aPD1 and OVA-aPD1 N.M.P groups elicited the increase of OVA-specific CD8+ TRMs, although there were also significant differences between the two groups (Fig. 3C, ESI Fig. 2B†). Furthermore, the OVA-specific CD8+ TRMs of the OVA-aPD1 N.M.P with a high level of TNF-α and INF-γ were compared to other groups (Fig. 3D, ESI Fig. 2B†). Consistent with the stronger CD8+ T cells and CD8+ TRMs immune response of the OVA-aPD1 N.M.P, a robust tumor regression was also observed (Fig. 3E). In line with these results, the liver-to-body-weight ratio was significantly higher in the PBS and Emp N.M.P groups compared with the other two groups (ESI Fig. 2C†). As the survival curves show, in the majority of cases, the curves were consistent with the inhibition of tumor growth, whereby the groups with smaller tumor sizes survived longer. Such survival was particularly notorious in two of the groups in which the tumor was not initially detectable. Only the OVA-aPD1 N.M.P group maintained 100% survival of the animals for more than five months after vaccine immunization (Fig. 3F). The H&E (ESI Fig. 2D†) and Ki67 (cell proliferation) (Fig. 3G) images showed more serious cell apoptosis with extensively damaged areas and cell proliferation areas in the control groups than the OVA-aPD1 N.M.P groups under the same conditions. These findings clearly demonstrated that OVA-aPD1 N.M.P could effectively boost strong systemic antitumor immune responses for synergistically suppressing the tumor growth.
Tumor-specific CD8+ TRMs that infiltrate tumor sites often fail to control tumor growth due to exhaustion or dysfunction sculpted by the immunosuppressive TME. Thus, the circuitous immunotherapy route that first activates the non-tumor antigen-specific TRMs and then activates the tumor antigen-specific T cells by intercellular cross-talk may be a viable route. Overall, OVA-aPD1 N.M.P immunization could highly activate the local CD8+ TRMs, and then indirectly activate T cell immunity through cytokine crosstalk. With the PD1 antibody and the adjuvant effect of the PLGA nano/microparticles, OVA-aPD1 N.M.P immunization can further improve the immune effects for the synergistic inhibition of both the primary and distal HCC tumor growths, which might provide a promising therapeutic vaccination strategy for potentiating HCC immunotherapy.
The scRNA-seq dataset of T cells was further investigated. T cells of the liver from OVA-aPD1 N.M.P had significantly higher expression genes of SATB1, CCL3, CCR7, LEF1, S1PR1, CD8B1, TCF7, FOXP1, NR4A2, CCL5, CTLA2 and KLF3, but lower expression genes of CXCL2, ATF3 and APOE (ESI Fig. 4D†). CD8+ T cells with a TRM phenotype can be identified as co-expressing transcripts for ITGAE, CXCR6, RUNX3 and CD69 (ESI Fig. 4B†), and there is evidence for these cells expressing high amounts of CD7, GZMA, NR4A2 and ITGA1 in the OVA-aPD1 N.M.P group (Fig. 4D). Heatmap analysis demonstrated that the immunotherapy group has a distinct set of up-regulated genes of CD8+ TRM, including that of different treatments (ESI Fig. 4D†).
Additionally, the Monocle 2 algorithm was used to perform pseudotime analysis. Two evolution fates of CD8+ T cells were found, one leading to inhibitory T cells and one leading to CD8+ TRMs (Fig. 4E, ESI Fig. 5A†). The trajectory began with CD8 naive T cells, followed by CD8 cytotoxic T cells. Then, some CD8 cytotoxic T cells ended with exhausted T cells, while some transformed into CD8+ TRMs (Fig. 4F).
CellChat is a tool based on gene expression and curated knowledge of communication information, such as receptors, ligands and their interactions, from known databases.32 Here, we analyzed the cell–cell interaction between T cells. Strikingly significant interactions were found between CD8+ TRMs, cytotoxic CD8+ T cells and NKT cells within immunotherapy. The number and strength of T cell subtype interactions of the OVA-aPD1 N.M.P group (Fig. 5A, ESI Fig. 5B†) were significant higher compared to the control (ESI Fig. 5C and D†). Moreover, the CCL, ICAM, ITGAL, MHC1, TNF-α signaling pathways were enriched in CD8+ TEMs and TRMs after infection (Fig. 5B). Transcription factors (TFs) and their downstream-regulated genes constitute a complex and intermingled network of gene regulation, which determines and maintains cell identity (Fig. 5C).
Single-cell regulatory network inference and clustering (SCENIC) analysis was performed to infer the activity of regulons (a TF together with its target genes comprise a regulon) for the CD8+ TRMs from the two groups. The regulon modules based on the regulon crosstalk (regulon-to-regulon correlation) were determined by the Connection Specificity Index (CSI) that ranks the regulon significance and mitigates the effects of nonspecific interactions. The analysis of the control and therapy group led to 16 regulons across four regulon modules (Fig. 5D). Comparison of the activity of the four modules revealed that module 1, including the TFs of CREB3L2, ARID5B, ELK3, ATF6, E2F1, KDM5A, SREBF2 and CREM, displayed the highest regulation activity in CD8+ TRMs from the OVA-aPD1 N.M.P group (ESI Fig. 5E†). Taken together, these findings indicated that OVA-aPD1 N.M.P may play a critical role in forming an activated liver local immunoenvironment by enhancing the immunoprotect effect of CD8+ TRMs and related genes.
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4nr00554f |
‡ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2024 |